Form 4: STOK CFO Leggett Acquires Shares via RSU Vesting

Stoke Therapeutics' Chief Financial Officer, Thomas Leggett, acquired 14,750 shares of common stock through the vesting of restricted stock units.

Summary

• Thomas Leggett, Chief Financial Officer of Stoke Therapeutics, Inc. (STOK), acquired 14,750 shares of common stock.
• The acquisition occurred on March 15, 2026, through the settlement of Restricted Stock Units (RSUs).
• The shares were acquired at a price of $0, which is typical for RSU vesting.
• Following this transaction, Mr. Leggett directly beneficially owns 14,750 shares of common stock.
• He also beneficially owns 44,250 derivative securities (RSUs) after this transaction.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a slightly positive event, as it indicates an executive's continued equity stake and commitment to the company through a standard compensation mechanism.

Positives

• Chief Financial Officer Thomas Leggett increased his direct beneficial ownership of common stock by 14,750 shares, indicating continued alignment with shareholder interests.
• The vesting of RSUs demonstrates the company's commitment to long-term incentive plans for its executives.

Negatives

• No negative information is presented in this routine insider transaction filing.

Risks

• Future stock price fluctuations could impact the value of the acquired shares and remaining RSUs.
• The vesting of RSUs is contingent on continued service, posing a risk to the executive if employment ceases.

Future Outlook

The remaining 44,250 Restricted Stock Units will continue to vest annually in 1/4 increments beginning March 15, 2026, subject to Mr. Leggett's continued service to Stoke Therapeutics.

Industry Context

StockSavvy.ai notes that RSU vesting is a common form of executive compensation, aligning management's interests with long-term company performance and shareholder value. This routine filing reflects the standard operation of such incentive programs within the biotechnology industry.

Stakeholder Impact

• Shareholders: The transaction shows continued alignment of executive interests with shareholders through equity ownership.
• Employees: Reflects the company's standard executive compensation practices.

Next Steps

• Future annual vesting of the remaining 44,250 Restricted Stock Units, contingent on continued service.

Key Dates

Keywords

Stoke Therapeutics, STOK, Form 4, Insider Transaction, Restricted Stock Units, RSU, Executive Compensation, Thomas Leggett, CFO, Stock Acquisition